

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/061,216	02/04/2002	Gregory P. Pogue	43276	3510
7590 03/22/2006			EXAMINER	
John C. Robbins			HILL, MYRON G	
Intellectual Pro	perty Department			
Large Scale Biology Corporation			ART UNIT	PAPER NUMBER
3333 Vaca Valley Parkway, Suite 1000			1648	
Vacaville, CA 95688			DATE MAILED: 03/22/2006	

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary    10/061,216   POGUE ET AL.	addrose .
Myron G. Hill 1648	addross
	eddross
The MAILING DATE of this communication appears on the cover sheet with the correspondence	addroce
Period for Reply	audress
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).	
Status	
1) Responsive to communication(s) filed on 27 October 2005.	
2a) ☐ This action is <b>FINAL</b> . 2b) ☒ This action is non-final.	
3) Since this application is in condition for allowance except for formal matters, prosecution as to the	he merits is
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.	
Disposition of Claims	
4)⊠ Claim(s) <u>79-99</u> is/are pending in the application.	
4a) Of the above claim(s) is/are withdrawn from consideration.	
5) Claim(s) is/are allowed.	
6)⊠ Claim(s) <u>79-99</u> is/are rejected.	
7) Claim(s) is/are objected to.	
8) Claim(s) are subject to restriction and/or election requirement.	
Application Papers	
9) The specification is objected to by the Examiner.	
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.	
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).	
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37	CFR 1.121(d).
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form F	PTO-152.
Priority under 35 U.S.C. § 119	
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).	
a) All b) Some * c) None of:	
1. Certified copies of the priority documents have been received.	
2. Certified copies of the priority documents have been received in Application No	
3. Copies of the certified copies of the priority documents have been received in this National	al Stage
application from the International Bureau (PCT Rule 17.2(a)).	
* See the attached detailed Office action for a list of the certified copies not received.	
Attachment(s)	
1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)	
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (P Other:	TO-152)

Art Unit: 1648

#### **DETAILED ACTION**

The Group and/or Art Unit of your application has changed. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Group Art Unit 1648, Examiner M. Hill.

### Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 10/27/2006 has been entered.

Claims 79-99 are under consideration.

## Rejections Necessitated By Amendment

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

### Claim Objections

Art Unit: 1648

Claim 95 is objected to because of the following informalities: "parenteral" appears to be misspelled. Appropriate correction is required.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 92-95 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. It is not clear if the sample is concentrated by the extraction or if the sample is already concentrated.

## Claim Rejections - 35 USC § 103

Claims 79-99 are rejected under 35 U.S.C. 103(a) &s being unpatentable over Garger *et al.* (US 6,033,895), (US 6,037,454), (US 6,303,779 B1) or (US 6,740,740 B2), each in the alternative, Koprowski *et al.* (US 6,042,832) and Francon *et al.* (US 5,075,110).

The claims are drawn broadly to a method of extracting virus from plants.

Applicant has amended claims to clarify the invention and added claims to further emphasize the steps of the inventive method.

Applicant agues that the solvent extraction is used to make the composition safe for injection, as shown in Example 8 and new claims 97 plus, and that the volume undergoing extraction is less than the original volume of

Art Unit: 1648

green juice and the concentration of virus is adjusted, this is shown in Table 1 and newly added claims 92 plus.

Applicant's arguments have been fully considered, but are not persuasive.

The method is recited with steps "comprising" and are thus open to other steps. The limitation in "final" in claims 90 and 97 do not indicate absolute finality. It would be obvious to stop at any point in the purification process and forgo the benefits of additional purification.

Applicant's argument that the extraction is for a different purpose is not persuasive because the sample is treated the same way in each and the different reasons do not alter the step. Claim 97 recites that the organic extraction is to purify. Furthermore, one of ordinary skill in the art at the time of invention would have known that virus expressed in plants can be used as vaccines or pharmaceutical/therapeutic compositions (Garger *et al.* column 1, lines 25-28). One of ordinary skill in the art at the time of invention would have known the level of purity or crudeness required for a composition for injection in animals or humans. Garger *et al.* teach optimization of extraction protocols and volumes used in general including that samples are concentrated 1-30 fold (column 7, lines 60-65) and that resuspention volumes and extraction steps effect virus yield (see at least Tables 3-8). The ranges and components as recited in claim 91 have been addressed before and are within ranges known or taught in the art. The Na<sub>2</sub>S<sub>2</sub>O<sub>5</sub> is used Garger *et al.* (Column 6, line 9).

Thus, the claims are unpatentable.

Art Unit: 1648

### Conclusion

No claim is allowed.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**.

See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Myron G. Hill whose telephone number is 571-272-0901. The examiner can normally be reached on 8:30 am-5 pm Mon-Fri.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on 571-272-0902. The fax

Art Unit: 1648

phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Myron G. Hill Patent Examiner 3/16/06

Pervisory patent examiné Technology center 1600